US HB9635 | 2025-2026 | 119th Congress
Status
Sponsorship: Partisan Bill (Democrat 1)
Status: Introduced on July 9 2026 - 25% progression
Action: 2026-07-09 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on July 9 2026 - 25% progression
Action: 2026-07-09 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To amend the Federal Food, Drug, and Cosmetic Act to establish special rules to provide for continued review of human drug and device submissions during a lapse of appropriations, and for other purposes.
Title
Getting Innovations to Patients During Shutdowns Act
Sponsors
| Rep. Kevin Mullin [D-CA] |
History
| Date | Chamber | Action |
|---|---|---|
| 2026-07-09 | House | Referred to the House Committee on Energy and Commerce. |
| 2026-07-09 | House | Introduced in House |
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/119th-congress/house-bill/9635/all-info |
| Text | https://www.congress.gov/119/bills/hr9635/BILLS-119hr9635ih.pdf |
